01 April 2008
Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: A convenient treatment option in advanced gastric cancerYulia Kundel, Ofer Purim, Arie Figer, Salomon M. Stemmer, Thomas Tichler, Jaqueline Sulkes, Aaron Sulkes, Baruch Brenner
Med Sci Monit 2008; 14(4): CR190-195 :: ID: 850286
Background: To summarize our experience using a regimen of weekly 5-FU and leucovorin (LV) and biweekly cisplatin (CDDP) in advanced gastric cancer (AGC).
Material/Methods: Patients had previously untreated histologically confirmed AGC. Treatment consisted of intravenous weekly infusional 5-FU and LV and biweekly CDDP, given for 6 weeks followed by a 2-week rest. Initially, a lower dose level was used (5-FU 2000 mg/m2, LV 500 mg/m[sup]2[/sup], CDDP 40 mg/m[sup]2[/sup]), which was later increased (5-FU 2600 mg/m[sup]2[/sup], LV 500 mg/m[sup]2[/sup], CDDP 50 mg/m[sup]2[/sup]).
Results: Forty-five patients were treated, 18 at the lower dose level and 27 at the higher dose level. The median age was 67 years and 55% were male. Grade ≥3 toxicity was documented in 37% of patients but toxicity related hospitalizations or treatment discontinuation occurred in only 22% and 13%, respectively. There were no toxic deaths. The most common hematological toxicities were anemia and neutropenia and the most common non-hematological toxicities were nausea, vomiting and fatigue. Of the 39 patients evaluable for response, 13 (33%) had partial response (PR) and 11 (28%) had stable disease (SD). Control of disease (PR+SD) was achieved in 61%. The higher dose level was associated with a higher response rate (p=0.07) and an increased toxicity (p=0.01), mostly hematological and gastrointestinal. Median progression-free survival and overall survival were 3.5 and 9.2 months, respectively.
Conclusions:This regimen appears safe, with a manageable toxicity profile. Efficacy data resemble those reported for more complex and toxic regimens. The higher dose level had enhanced activity, at the expense of increased toxicity.
Keywords: Fluorouracil - therapeutic use, Time Factors, Survival Rate, Neoplasm Staging, Leucovorin - therapeutic use, Infusions, Intravenous, Drug-Related Side Effects and Adverse Reactions, Dose-Response Relationship, Drug, Disease Progression, Cisplatin - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Aged, 80 and over
01 June 2023 : EditorialEditorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic Preparedness
Med Sci Monit 2023; 29:e941209
07 Jun 2023 : Review articleUltrasound-Guided Brachial Plexus Block by Costoclavicular Space Approach: A Narrative Review
Med Sci Monit In Press; DOI: 10.12659/MSM.939920
05 Jun 2023 : Clinical ResearchComparison of Texture and Color Enhancement Imaging with White Light Imaging in 52 Patients with Short-Segm...
Med Sci Monit In Press; DOI: 10.12659/MSM.940249
05 Jun 2023 : Laboratory ResearchComparison of Composite Resin (Duo-Shade) Shade Guide with Vita Ceramic Shades Before and After Chemical an...
Med Sci Monit In Press; DOI: 10.12659/MSM.940949
02 Jun 2023 : Database AnalysisThe COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in Poland
Med Sci Monit In Press; DOI: 10.12659/MSM.940904
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : EditorialEditorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...
Med Sci Monit 2022; 28:e935952